An SGLT2 inhibitor combined with a nonsteroidal mineralocorticoid receptor antagonist quickly cut urinary albumin-to-creatinine ratio (UACR) in patients with albuminuria and both chronic kidney disease (CKD) and type 2 diabetes, a randomized trial found.

Among 818 patients, finerenone (Kerendia) plus empagliflozin (Jardiance) reduced UACR by 52% from baseline to day 180 (least squares [LS] mean ratio 0.48, 95% CI 0.44-0.54), Rajiv Agarwal, MD, of the Richard L. Roudebush VA Medical Center in Indianapolis, reported at the European Renal Association (ERA) annual congress .

The UACR reduction achieved by combining these two agents was 29% greater than results with finerenone alone and 32% greater than with empagliflozin alone ( P <0.001 for both).

The UACR reduction achieved with combi

See Full Page